MD Newsline Metabolic Brief

In this episode of MD Newsline, Dr. Mohamed Abu-Farha, Principal Scientist at the Dasman Diabetes Institute in Kuwait, explores groundbreaking research into the relationship between portal insulin exposure, insulin resistance, and metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as fatty liver disease. Drawing from findings presented at ADA 2026, Dr. Abu-Farha explains how C-peptide measurements, ANGPTL8, and advanced metabolic phenotyping may improve clinicians' ability to identify patients at risk for liver fat accumulation without relying solely on imaging. He also discusses the future of predictive algorithms, GLP-1 therapies, insulin sensitizers, and precision medicine for diabetes care. Episode Highlights Understanding Portal Insulin and Liver Fat Dr. Abu-Farha explains why portal insulin concentration—rather than circulating insulin alone—may be a critical driver of liver fat accumulation. Because insulin travels directly from the pancreas to the liver through the portal vein, elevated portal insulin in insulin-resistant individuals may stimulate excessive fat storage in the liver. Why C-Peptide Matters Instead of measuring insulin alone, Dr. Abu-Farha highlights the importance of C-peptide as a more accurate reflection of pancreatic insulin production. Since insulin is partially cleared by the liver while C-peptide is not, C-peptide provides a better estimate of true portal insulin exposure. ANGPTL8 and Fatty Liver Development After more than a decade of research, Dr. Abu-Farha's team believes ANGPTL8 may serve as a biological link between hyperinsulinemia and hepatic fat accumulation. Their work shows strong associations between ANGPTL8, insulin resistance, triglyceride metabolism, and liver fat, opening new avenues for mechanistic and therapeutic research. Comparing Type 1 and Type 2 Diabetes Dr. Abu-Farha discusses why people with Type 1 diabetes generally develop less liver fat than those with early Type 2 diabetes. The difference, he explains, lies in the pattern of insulin delivery—subcutaneous insulin bypasses the portal circulation, whereas endogenous insulin production creates much higher portal insulin concentrations that may promote liver fat accumulation. Predicting Fatty Liver Without MRI One of the most promising aspects of Dr. Abu-Farha's research is the development of a mathematical prediction model capable of estimating liver fat using routine clinical measurements. Early findings show correlations exceeding 90% compared with imaging-based assessments, potentially making liver fat screening faster, less expensive, and more accessible. Practical Tools for Clinicians The research also demonstrates that readily available clinical measurements—including waist circumference and other metabolic indices—can provide strong estimates of fatty liver risk, helping physicians identify patients who may benefit from additional evaluation before advanced imaging is required. Rethinking Diabetes Therapy Dr. Abu-Farha discusses why reducing reliance on insulin, when clinically appropriate, may benefit some patients with Type 2 diabetes. Combining GLP-1 receptor agonists with insulin sensitizers could address the underlying causes of diabetes—obesity and insulin resistance—while potentially reducing long-term complications associated with excessive insulin exposure. The Future of AI and Precision Medicine Looking ahead, Dr. Abu-Farha envisions artificial intelligence and predictive algorithms becoming integrated into routine diabetes care. By combining metabolic biomarkers with simple clinical measurements, physicians could better estimate insulin resistance and fatty liver risk during everyday office visits. Next Steps in Research Future studies aim to directly test the portal insulin hypothesis in humans, including evaluating medications that suppress insulin production to determine their effect on liver fat accumulation. Dr. Abu-Farha believes these studies could provide definitive evidence supporting the proposed mechanism. Advances in Diabetes Treatment Dr. Abu-Farha concludes by highlighting the rapid evolution of diabetes therapies, including GLP-1 receptor agonists, amylin analogs, SGLT2 inhibitors, and emerging peptide-based treatments. He notes that developing safer and more effective insulin sensitizers remains an important unmet need in diabetes management. Key Takeaway Dr. Abu-Farha's research suggests that portal insulin exposure, insulin resistance, and ANGPTL8 signaling may play a central role in the development of MASLD (fatty liver disease). By combining routine clinical measurements, predictive algorithms, and a deeper understanding of disease biology, clinicians may soon be able to identify patients at risk earlier, reduce reliance on expensive imaging, and deliver more personalized diabetes care that targets the underlying mechanisms of metabolic disease.     Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact with Dr. Mohamed Abu-Farha: Here

In this episode of MD Newsline, Dr. Adrienne Youdim, an internist, obesity medicine specialist, and certified mind-body medicine physician, explores the often-overlooked emotional and psychological dimensions of obesity and diabetes care. Speaking from the American Diabetes Association (ADA) Scientific Sessions, Dr. Youdim explains why treating physical hunger alone is not enough, even in the era of GLP-1 medications. She discusses how stress, trauma, emotional regulation, and self-compassion influence hunger hormones, patient behaviors, and long-term health outcomes. Dr. Youdim also shares practical ways clinicians can incorporate mind-body medicine, breathing exercises, mindfulness, journaling, and compassionate communication alongside evidence-based obesity treatments to improve both physical and emotional well-being. Episode Highlights Understanding the "Hidden Hungers" Dr. Youdim introduces the concept of hidden hunger—the emotional, psychological, and spiritual needs that often drive eating behaviors beyond physical hunger. While GLP-1 medications effectively reduce appetite, they do not address underlying emotional stress, trauma, or unmet psychological needs that influence long-term health. How Stress Changes Hunger Hormones Stress affects the body's biology as much as its emotions. Dr. Youdim explains how acute stress and adverse childhood experiences increase ghrelin, the hormone responsible for stimulating hunger. This physiologic connection helps explain why chronic stress often leads to overeating and why addressing emotional health is an essential part of obesity treatment. Mind-Body Medicine as Clinical Care Mind-body practices such as breathing exercises, mindfulness meditation, yoga, expressive writing, and self-compassion training can reduce stress, improve emotional regulation, and encourage healthier behaviors. Dr. Youdim discusses how these evidence-based interventions can be easily integrated into routine clinical visits alongside medication therapy. Addressing Weight Stigma with Compassion Many patients arrive with previous experiences of weight bias and stigma that interfere with medical care. Dr. Youdim explains how brief breathing exercises and compassionate communication help establish trust, improve patient engagement, and create a safer clinical environment before discussing treatment plans. Diabetes, Food Anxiety, and Emotional Well-Being Patients living with diabetes often develop an intense focus on food choices, blood sugar, and body weight. While nutritional awareness is important, Dr. Youdim cautions that excessive attention to numbers may contribute to guilt, shame, self-stigma, and unhealthy relationships with food if not balanced with compassion. Finding the Right Balance When Discussing Weight Avoiding conversations about weight can be just as harmful as approaching them insensitively. Dr. Youdim encourages clinicians to engage patients in open, respectful conversations that acknowledge emotions, encourage self-compassion, and individualize discussions based on each patient's comfort level. GLP-1 Medications Within a Holistic Treatment Strategy Rather than replacing lifestyle change, GLP-1 medications reduce food noise and compulsive eating, allowing patients to better engage with nutrition, exercise, emotional healing, and behavioral change. Dr. Youdim views medications, behavioral therapy, and mind-body medicine as complementary components of comprehensive obesity care. Burnout, Leadership, and Hidden Hunger The same emotional deprivation affecting patients also contributes to clinician burnout and workplace challenges. Dr. Youdim explains how unmet emotional and relational needs can reduce resilience, impair decision-making, and negatively affect professional performance, making emotional wellness equally important for healthcare providers. Practical Tools for Patients and Clinicians Dr. Youdim recommends practical daily interventions including breathing exercises, mindfulness apps, journaling, body scans, and expressive writing. She emphasizes that physicians should first practice these techniques themselves before introducing them to patients, creating more authentic and effective care. Key Takeaway Dr. Adrienne Youdim emphasizes that the future of obesity and diabetes care extends far beyond medications alone. By recognizing hidden emotional hunger, addressing stress and trauma, integrating mind-body medicine, and combining these approaches with GLP-1 therapies and compassionate communication, clinicians can provide more comprehensive, patient-centered care that supports lasting physical and emotional health. Resources MD Newsline Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Learn more about Dr. Adrienne Youdim: Here

In this episode of MD Newsline, Dr. Kanhaiya Singh, associate professor at the University of Pittsburgh, discusses his research into vasculogenic fibroblasts and their potential role in healing diabetic and ischemic wounds. He explains how a subset of fibroblasts can acquire vasculogenic properties while retaining their fibroblast identity, a process he describes as a state change rather than a fate change. Dr. Singh explores how diabetes and epigenetic changes can suppress the generation of vasculogenic fibroblasts, the role of miR-200b in regulating this process, and findings from lineage-tracing studies in animal models. He also discusses tissue nanotransfection as a potential approach for delivering anti-miR-200b to wound tissue and the remaining steps needed to move this research toward clinical applications. Episode Highlights: The Discovery of Vasculogenic Fibroblasts Dr. Singh explains how single-cell RNA sequencing and subsequent experiments revealed a fibroblast population with vasculogenic properties. Unlike a conventional cell-fate change, these cells retain fibroblast characteristics while acquiring endothelial-like functions, leading the researchers to describe them as vasculogenic fibroblasts. State Change Rather Than Cell Fate Change The discussion explores the distinction between a cell changing its fate and acquiring a new functional state. Dr. Singh explains that vasculogenic fibroblasts continue to maintain fibroblast properties while taking on vasculogenic functions, allowing specific fibroblast subsets to participate in vascular repair without completely becoming endothelial cells. How Diabetes Suppresses Vasculogenic Fibroblasts Dr. Singh discusses how the diabetic microenvironment can interfere with vasculogenic fibroblast generation. He describes the role of hyperglycemia, DNA methyltransferases, and DNA hypermethylation in suppressing the endothelial program needed for vasculogenic fibroblast production. The Role of miR-200b The conversation examines miR-200b, an epigenetic regulator that plays a central role in the emergence of vasculogenic fibroblasts. Dr. Singh explains how elevated miR-200b in diabetic fibroblasts may limit their vasculogenic capacity and how reducing miR-200b can promote the phenotype needed for vascular repair. Lineage Tracing and Vasculogenic Fibroblast Evidence Dr. Singh describes experiments using Col1a2-Cre mouse models and lineage tracing to investigate whether fibroblasts contribute directly to vascular structures. He discusses findings showing fibroblast lineage-labeled cells within CD31-positive blood vessels and explains how spatial transcriptomics is helping identify the fibroblast subsets involved in this process. Vasculogenic Fibroblasts in Chronic Wounds The discussion highlights how vasculogenic fibroblasts are diminished in chronic, diabetic, and ischemic wounds. Dr. Singh shares findings from mouse models suggesting that increasing the proportion of vasculogenic fibroblasts can improve wound closure and perfusion. Tissue Nanotransfection and miR-200b Targeting Dr. Singh explains how tissue nanotransfection uses a silicon chip with microneedles and a pulsatile electrical current to deliver genetic cargo into tissue. In this research, the approach is being used to deliver an antisense oligonucleotide targeting miR-200b with the goal of restoring vasculogenic activity within wound tissue. From Preclinical Research Toward Clinical Translation The interview explores what remains between the current research and potential clinical studies. Dr. Singh discusses ongoing work with human skin explants, the development of a proprietary wound-healing model, and efforts to make the tissue nanotransfection device FDA-compatible before advancing toward clinical applications. The Future of Epigenetic Biomarkers in Diabetic Wound Care Looking ahead, Dr. Singh highlights epigenetics as an important area of research, particularly the development of biomarkers that could help predict whether diabetic wounds will heal or recur. He also discusses the potential role of artificial intelligence in analyzing single-cell data and developing predictive biomarkers through the Diabetic Foot Consortium. Key Takeaway Vasculogenic fibroblasts represent a distinct fibroblast state that may contribute to vascular repair during wound healing. Dr. Singh's research suggests that diabetes can suppress this reparative capacity through epigenetic mechanisms involving miR-200b, while approaches such as tissue nanotransfection may offer a potential way to restore vasculogenic activity. Although this work remains in the preclinical and translational research stage, continued investigation into epigenetic biomarkers and tissue reprogramming could help advance new approaches to diabetic wound healing. Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/

In this episode of MD Newsline, Dr. Sharita Golden, Professor of Endocrinology, Diabetes, and Metabolism at Johns Hopkins University School of Medicine, explores how achieving better diabetes outcomes requires addressing not only clinical care, but also health equity, social determinants of health, and system-level change. Drawing from decades of clinical practice, research, and advocacy, Dr. Golden explains how healthcare systems, public policy, culturally tailored interventions, and community partnerships can improve diabetes care for marginalized populations. She also discusses practical strategies clinicians can use to identify patient barriers, reduce disparities, and deliver more equitable, patient-centered care. Episode Highlights Rethinking Safe Glucose Management in the Hospital Dr. Golden reflects on her early experiences as a hospital endocrinologist, where she observed that inpatient systems often contributed to unsafe glucose management. She explains how standardized protocols, proactive insulin management, and evidence-based order sets can significantly improve patient safety and reduce complications such as hypoglycemia and hyperglycemia. Looking Beyond the Patient to the Healthcare System Health equity begins by asking what systemic barriers prevent patients and clinicians from achieving the best outcomes. Dr. Golden discusses how implementing standardized policies, clinical decision support, and quality improvement initiatives across multiple hospitals helped reduce disparities in diabetes care throughout an entire health system. Poverty as a Major Driver of Diabetes Disparities While racial and ethnic disparities remain important, Dr. Golden emphasizes that poverty and socioeconomic disadvantage often underlie poor diabetes outcomes across many communities. Limited access to healthcare, healthy food, safe environments for exercise, and transportation all contribute to persistent inequities in diabetes management. Why Social History Is Essential to Good Diabetes Care Dr. Golden encourages clinicians to ask open-ended questions that uncover the real-life challenges patients face. She shares a powerful example of a caregiver whose diabetes dramatically improved only after discussing the practical barriers preventing her from taking insulin consistently. Understanding a patient's daily life is often more valuable than simply adding medications. Culturally Tailored Care Improves Outcomes Successful diabetes interventions respect patients' cultural backgrounds and lifestyles. Dr. Golden explains how personalized nutrition counseling, community health workers, patient navigators, and delivering care in trusted community settings can substantially improve engagement and long-term diabetes control. Using Data to Drive Health Equity Collecting quality metrics is only the first step. Dr. Golden explains how stratifying data by geography, insurance status, and demographics enables health systems to identify underserved populations and develop targeted interventions such as telehealth programs, rural outreach clinics, and community-specific resources. The Role of Policy and Physician Advocacy Clinicians can extend their impact beyond the examination room by engaging with legislators and advocating for policies that improve access to care. Dr. Golden encourages healthcare professionals to share patient stories with policymakers to help shape legislation addressing diabetes disparities and broader public health challenges. Building Equity Through Community Partnerships Dr. Golden discusses how academic medical centers and community organizations can work together to expand successful diabetes care models. Investments in data infrastructure, quality improvement leaders, and community partnerships are essential for making equity-focused interventions sustainable across diverse healthcare settings. Moving Upstream to Address Social Determinants of Health Improving diabetes outcomes requires addressing the underlying social conditions affecting patients' lives. Dr. Golden illustrates how issues such as financial insecurity, housing instability, and utility access directly influence diabetes management, and how clinicians can connect patients with community resources while advocating for broader policy solutions. Expanding the Definition of Health Equity Dr. Golden concludes by emphasizing that diabetes inequities extend far beyond race and ethnicity. Rural communities, older adults, individuals living in poverty, and other marginalized populations all experience structural barriers to care. Addressing these shared challenges requires comprehensive solutions focused on improving access, affordability, and opportunity for every patient. Key Takeaway Dr. Golden demonstrates that better diabetes care requires more than prescribing medications—it demands addressing health equity, social determinants of health, system-wide quality improvement, culturally tailored interventions, and community partnerships. By listening carefully to patients, leveraging data, advocating for policy change, and redesigning healthcare systems, clinicians can reduce disparities and help every person living with diabetes achieve better health outcomes. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Sharita Golden: Here

In this episode of MD Newsline, Dr. Michael Albert, obesity medicine specialist, internist, and Co-Founder of Accomplish Health, joins Dr. Spencer Nadolsky, board-certified obesity physician, family physician, lipidologist, and Founder of Vineyard, for an expert roundtable on the rapidly evolving landscape of Medicare coverage for obesity treatment. They discuss how GLP-1 receptor agonists, evolving CMS policies, and the proposed Medicare bridge model are changing obesity care for older adults while highlighting the importance of personalized medicine, long-term chronic disease management, clinical documentation, and multidisciplinary care. The conversation also explores barriers to medication access, prior authorization challenges, care infrastructure, patient education, and how success in obesity treatment should be measured beyond the number on the scale. Episode Highlights Medicare Coverage and Access to GLP-1 Medications Drs. Albert and Nadolsky explain why the greatest barrier to obesity treatment is often not identifying appropriate patients—but helping them obtain and maintain access to therapy. They discuss Medicare Part D coverage, prior authorization requirements, step therapy, and how insurance policies frequently determine clinical decision-making. Understanding the Medicare GLP-1 Bridge Program The discussion examines proposed Medicare eligibility criteria for GLP-1 therapies, including BMI thresholds, cardiovascular disease, chronic kidney disease, hypertension, and other qualifying conditions. The physicians explain how these criteria differ from traditional FDA labeling and what clinicians need to document for approval. Building Clinical Infrastructure for Success Effective obesity care requires more than prescribing medication. Dr. Albert shares how custom EHR workflows, automated documentation, digital intake tools, and streamlined prior authorization systems help practices deliver high-quality obesity care at scale while reducing administrative burden. Personalizing GLP-1 Therapy for Older Adults Older adults require individualized treatment strategies to minimize frailty, sarcopenia, dehydration, and gastrointestinal side effects. The physicians discuss dose titration, oral versus injectable formulations, nutritional monitoring, resistance exercise, and shared decision-making to safely optimize treatment. Setting Expectations for Long-Term Treatment Obesity is a chronic disease that often requires lifelong management. Drs. Albert and Nadolsky emphasize informed consent, discussing medication costs, potential loss of coverage, weight regain after discontinuation, and the importance of preparing patients for long-term therapy. Documentation That Improves Access The panel reviews best practices for documenting obesity severity, BMI, ICD-10 coding, and obesity-related comorbidities such as diabetes, hypertension, obstructive sleep apnea, cardiovascular disease, and chronic kidney disease. Accurate documentation helps improve approval rates while supporting evidence-based care. Multidisciplinary Care and Care Coordination Managing obesity effectively requires collaboration among primary care physicians, obesity specialists, dietitians, cardiologists, endocrinologists, nephrologists, and bariatric surgeons. The physicians discuss referral pathways, closed-loop communication, digital health systems, and coordinated care models that improve patient outcomes. Measuring Success Beyond Weight Loss While weight reduction remains important, the physicians argue that true success should be measured by improvements in metabolic health, cardiovascular risk, mobility, functional independence, quality of life, medication reduction, and the ability to perform everyday activities—not simply achieving a target percentage of weight loss. Key Takeaway Drs. Albert and Nadolsky emphasize that obesity is a chronic disease, not simply a lifestyle issue, and effective treatment requires long-term access to GLP-1 medications, personalized care, thoughtful clinical infrastructure, multidisciplinary support, and patient-centered decision-making. As Medicare expands access to obesity therapies, success will depend not only on prescribing innovative medications but also on creating healthcare systems that deliver equitable, sustainable, and comprehensive obesity care while measuring outcomes by overall health, function, and quality of life rather than weight loss alone. Resources MD Newsline Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Featured Guests Dr. Michael Albert Co-Founder & Chief Medical Officer, Accomplish Health Obesity Medicine Specialist & Internist https://michaelalbertmd.com/ Dr. Spencer Nadolsky Founder, Vineyard Board-Certified Obesity Medicine Physician, Family Physician & Lipidologist https://drspencer.com/

In this episode of MD Newsline, Dr. Wanda Averhart a general pediatrician and obesity medicine specialist based in Chicago, shares practical insights into the rapidly evolving role of GLP-1 receptor agonists in primary care. Drawing from real-world clinical experience, she explores how these medications are transforming obesity management, patient outcomes, and long-term chronic disease care. Dr. Averhart breaks down the physiology of GLP-1s, explains how they impact appetite, metabolism, and insulin regulation, and discusses their growing role beyond diabetes treatment. She also provides a candid look at patient selection, titration strategies, side effect management, and the importance of setting realistic expectations for long-term therapy. From navigating insurance barriers to addressing social media-driven demand, this episode offers clinicians a grounded, practical framework for integrating GLP-1 therapies into everyday practice while maintaining patient safety and effectiveness. Episode Highlights: Understanding How GLP-1 Medications Work Dr. Averhart explains the three primary mechanisms of GLP-1 receptor agonists—enhancing insulin secretion, slowing gastric emptying, and reducing appetite through brain signaling—creating a powerful combined effect on weight and metabolic health. The Rising Demand for GLP-1s in Clinical Practice Over the past few years, interest in GLP-1 therapies has surged dramatically, driven by both clinical success and widespread public awareness, making obesity management a central focus in primary care. Patient Selection: Indications, Red Flags, and Individualization Appropriate prescribing begins with FDA-approved indications such as obesity, diabetes, or sleep apnea. Dr. Averhart emphasizes the importance of evaluating each patient holistically, including medical history, risks, and readiness for treatment. Titration Strategies and Real-World Flexibility While standard titration protocols exist, treatment is often individualized. Some patients remain on lower doses successfully, while others require escalation, highlighting the importance of patient-centered decision-making. Managing Common and Serious Side Effects Gastrointestinal symptoms like nausea and constipation are common early on and can often be managed with diet, hydration, and dose adjustments. Rare but serious risks such as pancreatitis and thyroid cancer require careful screening and monitoring. Monitoring Progress and Defining Treatment Success Dr. Averhart outlines key lab markers—including A1C, kidney function, thyroid levels, and cholesterol—and defines treatment success as achieving 5–10% weight loss within a few months at therapeutic doses. Long-Term Therapy and Weight Regain Realities GLP-1 medications are framed as long-term or lifelong treatments due to obesity being a chronic condition. Discontinuation often leads to rapid weight regain, making patient education and expectation-setting critical. Behavioral Health Considerations and Eating Disorders Screening for eating disorders is essential before initiating therapy. While some patients report reduced binge tendencies, GLP-1s are not a treatment for eating disorders and should be used cautiously in these populations. Access, Cost, and Insurance Challenges Coverage and prior authorizations heavily influence prescribing decisions. Clinicians must often adapt treatment plans based on what medications are accessible to patients. Future of GLP-1s and Emerging Therapies With new drugs and expanded indications on the horizon, GLP-1 therapies are poised to become standard care across multiple chronic conditions, reshaping the future of primary care medicine. Key Takeaway: Dr. Averhart emphasizes that GLP-1 medications are powerful tools for managing obesity and metabolic disease, but their success depends on careful patient selection, ongoing monitoring, lifestyle integration, and a clear understanding that these therapies are part of long-term chronic disease management.  Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact with Dr. Wanda Averhart: Here

In this episode of MD Newsline, a panel of experts—including Dr. Sharon Geisie, pediatric intensivist and GLP-1 Enhanced co-founder Dr. Aliza Olive, and clinical pharmacist Dr. Kelly Bader—explore how GLP-1 therapies are being used in real-world settings beyond clinical trials. The discussion highlights key differences between controlled study data and everyday patient experiences, offering practical insights into dosing, nutrition, sustainability, and long-term weight management. The panel dives into how GLP-1 medications have evolved from diabetes treatments to widely used tools for weight management, and why real-world data is essential for understanding patient outcomes, adherence, and long-term success. From managing side effects to preventing weight regain, this episode provides a comprehensive look at how clinicians and support systems can optimize care for patients using GLP-1 therapies. Episode Highlights: The Evolution of GLP-1 Therapies GLP-1 medications were initially developed for diabetes management but have rapidly expanded into weight loss and metabolic health. The panel discusses how their use has shifted toward a broader population—including individuals who may not meet traditional obesity criteria but still benefit from treatment. Real-World Data vs. Clinical Trials Clinical trials often focus on chronically obese populations, while real-world patients vary widely. The panel emphasizes that outcomes such as weight regain, adherence, and side effects can differ significantly outside controlled environments, highlighting the importance of real-world insights. Weight Loss vs. Weight Maintenance While much of the current research focuses on weight loss, the panel identifies weight maintenance as a critical and under-researched area. Many patients choose to remain on lower doses long-term to sustain results and avoid weight regain. The Importance of Personalized Dosing Standard dosing protocols may not work for every patient. Experts stress the need for individualized titration based on patient response and tolerability, noting that overly aggressive dose increases often lead to unnecessary side effects and discontinuation. Nutrition and Protein Intake Proper nutrition is a cornerstone of success with GLP-1 therapies. With reduced appetite, patients must prioritize nutrient-dense foods—especially protein—to preserve muscle mass, maintain metabolism, and prevent unwanted side effects like fatigue or hair loss. Managing Weight Regain and Tapering Off Many patients struggle with rapid weight regain after discontinuing GLP-1 medications. The panel highlights the importance of structured tapering strategies, reverse dieting, and sustainable habit-building to maintain long-term results. Behavior Change and Mindset Beyond physical changes, long-term success depends on addressing mindset and habits. The panel discusses the importance of realistic goal setting, avoiding extreme dieting mentalities, and focusing on sustainable lifestyle changes. Safety and Tolerability in Practice Real-world experiences reveal that many side effects—particularly gastrointestinal issues—can be minimized through slower dose escalation and better patient monitoring. Proper guidance can significantly reduce discontinuation rates. The Role of Technology and Community Emerging tools such as AI-powered apps, tracking platforms, and online communities are enhancing patient support. These technologies help individuals monitor progress, stay accountable, and access personalized guidance throughout their journey. The Future of GLP-1 Therapies The panel agrees that GLP-1 medications are here to stay, with growing applications in cardiovascular health, neurodegenerative diseases, and metabolic conditions. Future research is expected to focus on prevention, maintenance, and new delivery methods, including oral formulations. Key Takeaway GLP-1 therapies represent a powerful advancement in weight management, but their success depends on more than medication alone. Personalized dosing, proper nutrition, behavior change, and ongoing support are essential for achieving sustainable, long-term outcomes. Integrating real-world insights into clinical practice will be key to optimizing patient care in this rapidly evolving space. Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact with panelist: ·       Dr. Sharon Geisie: Here ·       Dr. Aliza Olive: Here

In this episode of MD Newsline, Dr. Dillon Bannis, an OB-GYN practitioner based in the South Side of Chicago, shares his insights on the evolving challenges and innovations in obstetric and gynecological care. Dr. Bannis explores how listening, collaboration, and technology are reshaping the patient experience—from prenatal care and delivery practices to addressing health disparities and integrating AI into medicine. With a strong emphasis on patient-centered communication, interdisciplinary collaboration, and technological integration, Dr. Bannis highlights how practitioners can balance innovation with compassion in women's healthcare. Episode Highlights: Bridging the Gap Between Innovation and Implementation Dr. Bannis discusses the lag between medical innovation and real-world practice, citing examples such as updated cervical cancer screening guidelines. He stresses that while medicine continues to advance rapidly, implementation often lags behind, emphasizing the need for better education, awareness, and adaptability among clinicians. The Power of Listening in Patient Care According to Dr. Bannis, listening is one of the most underrated skills in medicine. By prioritizing patient voices, physicians can build stronger relationships and facilitate shared decision-making, leading to more trusting and effective care outcomes. Advances in Obstetric Technology Dr. Bannis highlights promising innovations aimed at reducing maternal morbidity and mortality, particularly through hemorrhage prediction and prevention technologies. These tools, he explains, are transforming labor and delivery outcomes across practices. Cultural Competence and Birth Planning Drawing from his experience working alongside certified nurse midwives, Dr. Bannis advocates for respecting patients' birth preferences, whether it's squatting, all-fours positions, or doula-assisted births. He believes honoring cultural diversity in birthing methods contributes to better physical and emotional outcomes. Collaborative Care for High-Risk Pregnancies In complex cases involving oncology or high-risk pregnancies, Dr. Bannis underscores the importance of seamless communication between community and academic hospitals. He explains that efficient information sharing and inter-institutional collaboration can prevent medical errors and ensure no patient "falls through the cracks." Socioeconomic Factors and Health Disparities Dr. Bannis addresses how socioeconomic status affects access to prenatal care, nutrition, and birth outcomes. He calls for systemic efforts to tackle the social determinants of health and to make preventive screening more accessible to underserved populations. Empowering Patients Through Technology He emphasizes the importance of giving patients ownership of their medical records and using digital tools for education and engagement. By involving families and support systems, technology can enhance adherence, understanding, and long-term health outcomes. AI and the Future of Medical Communication Dr. Bannis envisions AI as a bridge between medical jargon and patient comprehension—translating complex medical notes into accessible summaries and breaking down language and cultural barriers. He also discusses how AI can streamline research and accelerate innovation in women's health. From Doulas to Robotics: The Expanding Role of Innovation Dr. Bannis explores the complementary roles of doulas, midwives, and robotic-assisted surgeries in modern OB-GYN care. He highlights that the field is moving from invasive solutions like hysterectomy toward minimally invasive and patient-preserving approaches, including uterine fibroid embolization. Key Takeaway: Dr. Dillon Bannis emphasizes that true progress in women's health lies at the intersection of empathy and innovation. By actively listening to patients, embracing technological advancement, and addressing health disparities, practitioners can create a more equitable, efficient, and compassionate healthcare system for all. Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Dillon Bannis: Here

In this episode of MD Newsline, Dr. Wanda Averhart, a general pediatrician and obesity medicine specialist, explores the complex causes and lifelong impacts of childhood obesity, emphasizing how early feeding practices, maternal health, and social disparities shape children's long-term outcomes. Dr. Averhart provides a comprehensive look at how environmental, cultural, and biological factors contribute to rising obesity rates among children—especially in underrepresented communities. She discusses the importance of infant feeding patterns, maternal diabetes and stress, and access to nutrition in determining early weight trajectories. Her insights reveal that addressing obesity begins before birth, and that family education and community-based interventions are key to prevention. Episode Highlights: Understanding Childhood and Infant Obesity Dr. Averhart explains that while "infant obesity" isn't technically defined, early feeding habits play a crucial role in a child's risk for obesity. Factors such as maternal health during pregnancy, feeding type, and cultural feeding practices all influence growth and metabolic outcomes. The Role of Feeding Practices and Culture From breastfeeding and formula feeding to early solid food introduction, Dr. Averhart emphasizes how cultural norms and parental beliefs shape feeding behavior. Introducing solid foods too early—especially high-sugar or fried foods—can increase obesity risk later in life. Environmental and Socioeconomic Factors She discusses how food deserts, limited access to fresh produce, and economic barriers make it difficult for many families to follow nutritional guidelines. Dr. Averhart highlights programs like WIC and SNAP that can provide critical nutritional support. Maternal Health and Stress Dr. Averhart outlines how maternal obesity, diabetes, and stress can biologically influence a child's future weight and metabolism through hormonal pathways like cortisol. She also connects maternal mental health to early childhood nutrition and caregiving quality. The Rise of Pediatric Comorbidities She notes an alarming increase in fatty liver disease, hypertension, and prediabetes among children—conditions once rare in pediatrics. These comorbidities disproportionately affect Black and Hispanic children and those from low-income households. Emerging Treatments and Future Research Dr. Averhart discusses the growing field of pediatric obesity treatment, including the use of GLP-1 receptor agonists (like semaglutide) in adolescents. However, she stresses that compassion, education, and prevention remain the most effective strategies. Key Takeaway: Dr. Averhart calls on healthcare providers to approach obesity with empathy and understanding, recognizing it as a chronic, relapsing condition. She encourages clinicians to combine medical management, cultural awareness, and community engagement to support children and families most at risk. Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Wanda Averhart: Here

In this episode of MD Newsline, Dr. Sassan Mirfakhraee, adult endocrinologist and associate professor at the University of Texas Southwestern Medical Center, shares groundbreaking insights into the management of adrenal insufficiency. At the Endocrine 2025 conference, Dr. Mirfakhraee presented his research on utilizing insulin pumps to deliver hydrocortisone—an innovative off-label approach that is showing promising results for patients who remain symptomatic on oral therapy. He explains how this strategy better mimics the body's natural cortisol rhythm, improves quality of life, and reduces ER visits and hospitalizations for patients with persistent symptoms. Dr. Mirfakhraee also outlines patient selection criteria, training protocols, safety considerations, and the potential for remote monitoring via pump data. This conversation highlights the importance of personalized care in endocrinology, bridging innovation with clinical practice to improve outcomes for patients with challenging conditions. Episode Highlights: New Approach to Adrenal Insufficiency Dr. Mirfakhraee introduces the use of insulin pumps for hydrocortisone infusion, addressing limitations of oral steroids that often fail to fully resolve symptoms. Mimicking Cortisol's Natural Rhythm The pump allows for overnight delivery and tailored boluses, reducing symptoms such as dizziness, nausea, fatigue, and morning crashes that patients often face with oral therapy. Patient Selection and Benefits He outlines which patients may benefit most—those with persistent symptoms, frequent adrenal crises, malabsorption issues, or shift-work challenges—while ensuring other conditions are ruled out. Remote Monitoring and Safety Insulin pumps enable cloud-based data sharing, allowing clinicians to monitor dosing, adjustments, and stress dosing remotely. While generally safe, clinicians must remain vigilant for issues like skin infections or infusion interruptions. Training and Quality of Life Through support from diabetes educators, patients learn how to manage pump settings and troubleshoot. Many report dramatic improvements—returning to work, engaging in family life, and regaining independence. Future Research Needs Dr. Mirfakhraee stresses the need for standardized pump settings, broader data collection, and insurance approval pathways to make this therapy more accessible. Key Takeaway: Insulin pump-based hydrocortisone delivery offers a promising new avenue for patients with adrenal insufficiency who remain symptomatic on oral therapy. By improving quality of life, reducing crises, and allowing for tailored dosing, this approach may represent a paradigm shift in endocrine care. Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Sassan Mirfakhraee:  Here

In this episode of MD Newsline, Dr. Alyson K. Myers, endocrinologist and Associate Chair for Faculty Mentoring and Community Engagement at Montefiore in the Bronx, dives into one of the most pressing and underrecognized complications of diabetes: diabetic foot ulcers (DFUs) and the devastating risk of amputations. She discusses the intersection of clinical care, social determinants of health, and healthcare disparities, while also highlighting emerging technologies and multidisciplinary clinic models designed to reduce risks and improve patient outcomes. Drawing on her extensive experience in diabetes management and community engagement, Dr. Myers emphasizes both the urgent need for systemic change and the practical tools clinicians can use today to protect their patients. Episode Highlights: High Amputation Risk in Diabetic Foot Ulcers Dr. Myers shares sobering statistics, noting that 44% of patients who present with a diabetic foot ulcer undergo an amputation within five years. This reality highlights the urgency of early screening, prevention, and intervention in diabetes care. She stresses that DFUs are not only medical complications but also markers of systemic inequity and missed opportunities for prevention. The Role of Social Determinants of Health Dr. Myers explores how socioeconomic status, racial disparities, and provider bias profoundly shape patient outcomes. In the Bronx and other underserved areas, patients often face delays in diagnosis, limited access to care, and inconsistent follow-up, all of which contribute to worse outcomes. She emphasizes the importance of addressing these systemic barriers alongside clinical treatment. Innovative Technology for Prevention Emerging tools, such as thermal-sensing mats and sensor-equipped socks, offer promising ways to identify foot ulcers before they progress. These devices can detect subtle temperature changes that indicate early tissue damage, allowing patients and providers to intervene earlier. Dr. Myers highlights the potential of technology to improve adherence and reduce disparities by making self-care more accessible. Building Multidisciplinary DFU Clinics Dr. Myers describes the creation of a multidisciplinary DFU clinic in the Bronx, modeled after programs at institutions like Stanford. By integrating endocrinology, podiatry, vascular surgery, infectious disease, and behavioral health, this model ensures that patients receive comprehensive, coordinated care. She explains how this approach can drastically reduce amputation rates and improve long-term patient outcomes. Patient and Caregiver Education Education remains a cornerstone of DFU prevention. Dr. Myers emphasizes strategies such as ensuring patients wear proper footwear, involving caregivers and family members in diabetes care, and simplifying self-care routines. She points out that community-based education and culturally sensitive approaches are essential for building trust and improving adherence. Advocacy and Policy Change Beyond clinical care, Dr. Myers stresses the importance of advocacy and systemic reform. She calls for insurance coverage expansion for proven therapies, including GLP-1 receptor agonists and PAD (peripheral arterial disease) screenings, which can significantly improve outcomes. Her message is clear: reducing disparities in diabetes care requires action at every level—from the exam room to healthcare policy. Key Takeaway: Diabetic foot ulcers are a leading cause of amputation, yet they remain preventable with the right tools and care models. Through early detection technologies, multidisciplinary clinics, culturally sensitive education, and equitable access to therapies, healthcare providers can dramatically improve patient outcomes and close persistent gaps in diabetes care. Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Alyson K. Myers:LinkedIn

In this episode of MD Newsline, Dr. Rachael Sood, a diabetes nurse practitioner and certified diabetes care and education specialist from New Orleans, Louisiana, shares her insights from the 85th American Diabetes Association Scientific Sessions. As the founder of The Diabetes Collective, Dr. Sood discusses the evolution of diabetology—a specialized field focused solely on the identification, treatment, and management of diabetes across all patient populations. Dr. Sood explores how personalized diagnostics, innovative technology, and education-driven care models are reshaping outcomes for patients with type 1, type 2, and prediabetes. She highlights the importance of accurate diagnosis, the role of genetic predisposition, and why clinicians must move beyond relying solely on hemoglobin A1C levels to ensure proper disease identification and management. Episode Highlights: Transforming the Diagnosis and Management of Diabetes Dr. Sood explains the principles of diabetology and how it differs from traditional endocrinology. She emphasizes comprehensive assessment, including antibody screening, glucose monitoring, and the integration of genomic insights to accurately distinguish between type 1 and type 2 diabetes. Technology as a Game-Changer in Diabetes Care Dr. Sood shares how continuous glucose monitors (CGMs) and insulin pumps have revolutionized real-time patient engagement. These smart biosensors empower patients to understand how lifestyle, stress, and nutrition directly affect glucose levels, fostering self-awareness and adherence to treatment plans. Overcoming Clinical Inertia and Patient Barriers She highlights the need to address clinical inertia, encouraging clinicians to adapt treatment plans as patients' needs evolve. Dr. Sood underscores the importance of patient education, empathy, and collaboration with family and community networks to improve adherence and reduce care fatigue. Breakthroughs in Treatment and Research Reporting from the ADA conference, Dr. Sood discusses the promising results of Vertex Pharmaceuticals' islet cell therapy, which shows evidence of restoring natural insulin production in type 1 diabetes. She also explains the role of TZLD (teplizumab) in delaying the onset of type 1 diabetes, potentially changing the disease trajectory for high-risk patients. Next-Generation Therapies and GLP-1 Innovation Dr. Sood breaks down the expanding role of GLP-1 receptor agonists—from glucose regulation to benefits in cardiovascular health, weight management, and chronic kidney disease. She reveals data on the new CagreSema combination therapy, which combines semaglutide with an amylin analog, showing over 20% weight reduction and improved metabolic outcomes. Insurance and Access Challenges Dr. Sood addresses the ongoing struggle of insurance coverage, prior authorizations, and high costs for new medications, offering practical advice for clinicians and patients to navigate access through manufacturer programs and cash-based options. Key Takeaway: Dr. Sood emphasizes that diabetes care is entering a transformative era—one defined by early detection, patient empowerment, and precision medicine. With new therapies, technologies, and care models emerging rapidly, collaboration among clinicians, patients, and innovators will be essential to achieving long-term success in diabetes prevention and management. Link & Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Rachael Sood: Here

In this episode of MD Newsline, Dr. Sarimar Agosto Salgado, Oncologic Endocrinologist at Moffitt Cancer Center, shares insights from a panel discussion at the AACE 2025 conference on the complexities of advanced thyroid cancer. She explores case-based approaches to recurrent, radioactive iodine-refractory disease and introduces the evolving strategy of re-differentiation therapy—a promising method for resensitizing tumors to radioactive iodine. Dr. Salgado also highlights real-world challenges including diagnostic errors, late referrals, and the need for greater access to multidisciplinary care. Episode Highlights: Understanding Radioactive Iodine-Refractory Disease Dr. Salgado explains that a subset of thyroid cancer patients no longer respond to radioactive iodine due to disease progression. For these patients, careful monitoring, local therapies like SBRT, or systemic treatments become necessary depending on the tumor's growth and location. Re-differentiation Therapy Explained She introduces re-differentiation—a technique using short-term targeted therapy (e.g., BRAF inhibitors) to restore the tumor's ability to uptake radioactive iodine. This allows for additional rounds of treatment and may delay or reduce the need for long-term systemic therapy. The Role of Real-World Data and Registries Because prospective clinical trials remain limited, Dr. Salgado advocates for collecting data through real-world registries and academic collaborations. These efforts may help define optimal timing, predictive markers, and response indicators for re-differentiation therapy. Challenges in Diagnosis and Timely Referral Dr. Salgado reflects on misdiagnosed cases, including rare thyroid variants confused with neuroendocrine tumors. She emphasizes the importance of early referral to expert centers before treatment limits available options. Access and Equity in Advanced Thyroid Cancer Many patients lack access to high-volume thyroid teams, leading to missed opportunities. Dr. Salgado urges clinicians to prioritize expert pathology review, molecular testing, and full-neck imaging to avoid delays in diagnosis and care. Key Takeaway: Advanced thyroid cancer is complex and often underestimated. Early referral, precision strategies like re-differentiation, and equitable access to expert teams are critical to improving outcomes and expanding hope for patients with this challenging disease. Resources & Links: Website: MD Newsline Newsletter: Subscribe Connect with Dr. Sarimar Agosto Salgado: Here

In this episode of MD Newsline, Dr. Omolara G. Adeniran, an endocrinologist practicing in Florida, shares her frontline experience addressing the complex realities of diabetes management, technology hesitancy, and healthcare disparities. Drawing on insights from the American Association of Clinical Endocrinology (AACE) conference, Dr. Adeniran discusses lipodystrophy, CGM technology, and how to navigate social determinants of health in real-world patient care. Episode Highlights: Recognizing Lipodystrophy and Treatment Overlap Dr. Adeniran highlights a key learning from the conference—a lecture on differentiating lipodystrophy from Cushing syndrome, a diagnostic challenge due to overlapping features. She shares how improved understanding of this rare condition can lead to significant improvement in comorbidities like severe insulin resistance and hypertriglyceridemia once correctly identified and treated. Breaking Down Technology Barriers with CGMs Continuous glucose monitoring (CGM) remains underutilized due to patient fears and insurance limitations. Dr. Adeniran explains her approach: providing demo models, offering trial periods, and giving reassurance about data privacy to help patients gain comfort with technology and improve their diabetes self-management. Navigating Insurance, Food Access, and Cultural Habits Insurance coverage, food deserts, and cultural food practices remain major obstacles. Dr. Adeniran shares strategies for working with patients in lower-resource settings, including promoting portion control, pragmatic dietary substitutions, and encouraging family involvement in nutrition and care. Engaging Patients in Shared Decision-Making From discussing A1C levels to blood pressure trends, Dr. Adeniran emphasizes making data relatable. She walks patients through lab comparisons over time and links clinical numbers to how they feel—helping them take ownership of their health. Emotional support and patient storytelling help reinforce behavior change. The Power of Listening and Small Steps According to Dr. Adeniran, patient progress starts with empathetic listening. She urges clinicians to hear the small clues that lead to big breakthroughs. Whether managing obesity, thyroid conditions, or diabetes, she believes in celebrating small wins and meeting patients where they are—both medically and personally. Key Takeaway: Effective endocrine care hinges on trust, technology, and tailored solutions. From CGM adoption to dietary adjustments, empowering patients with education and empathy is key to closing gaps and improving outcomes. Resources & Links: Website: MD Newsline Newsletter: Subscribe Here Connect with Dr. Omolara Adeniran: Here

In this episode of MD Newsline, Dr. Kamrun Naher, an endocrinologist based in Brooklyn, shares two compelling case studies that highlight how seemingly psychiatric symptoms and subtle complaints can conceal serious endocrine disorders. She recounts a rare case where suicidal behavior and insomnia led to the discovery of a neuroendocrine tumor in the pancreas, as well as a cluster of unexpected diagnoses of pheochromocytoma—a rare tumor of the adrenal glands. Dr. Naher underscores the need for multidisciplinary collaboration, greater awareness among providers, and earlier patient education to prevent delayed diagnoses and potentially life-threatening complications. Episode Highlights: Unmasking a Neuroendocrine Tumor A patient initially treated for psychiatric symptoms—including depression and insomnia—was ultimately found to have hypoglycemia-induced neuroendocrine tumor in the pancreas. Dr. Naher explains how a cascade of symptoms and an incidental CT scan led to a life-changing diagnosis and surgical treatment. Mental Health vs. Medical Misdiagnosis This case prompts a broader discussion on the importance of not attributing all behavioral health crises to psychiatric origins. Symptoms like insomnia and depression may sometimes be manifestations of metabolic or endocrine issues such as insulin-producing tumors. Pheochromocytoma in the Real World Dr. Naher reflects on a series of pheochromocytoma cases she diagnosed within one month—despite never seeing any during her fellowship. The episodic symptoms—palpitations, sweating, and chest pain—were often dismissed as normal or unrelated. These cases show how pattern recognition and detailed patient questioning can make a diagnostic difference. Preventing Missed Diagnoses Through Simple Questions Dr. Naher advocates for providers to ask patients: "What feels unusual or not normal to you?" This one question, she argues, could bring hidden symptoms to light and lead to earlier detection of rare but serious conditions. Data Collection and Global Awareness She also shares her vision for creating a global hub for rare case data, aiming to gather insight from providers worldwide to better identify trends, recognize genetic syndromes like MEN1, and promote broader awareness. Key Takeaway: Not every psychiatric symptom is psychiatric in origin. Early intervention, cross-disciplinary collaboration, and asking the right questions can uncover life-threatening endocrine disorders—and change the course of care. Resources & Links: Website: MD Newsline Newsletter: Subscribe Here Connect with Dr. Kamrun Naher: Here

In this episode of MD Newsline, Dr. Jamie Almandoz, Associate Professor at UT Southwestern Medical Center and Medical Director of the Weight Wellness and Obesity Medicine Program, discusses the evolving science of post-bariatric weight management, the rising use of GLP-1 medications, and the role of multidisciplinary care in treating obesity as a chronic illness. He shares practical insights into weight regain after bariatric surgery, how medications can support long-term outcomes, and the importance of nutrition, mental health, and individualized care. Episode Highlights: Understanding Post-Bariatric Weight Regain Dr. Almandoz explains why obesity is not cured by surgery and how weight regain—up to 40% on average—is common due to metabolic adaptation, hormonal shifts, and anatomical changes. He emphasizes the need to redefine success by health improvement, not just weight loss. The Role of GLP-1 and Incretin Therapies GLP-1 receptor agonists and other medications have become powerful tools in obesity management. Dr. Almandoz discusses their potential to support both pre- and post-surgical patients, how they affect hunger and calorie intake, and their limitations, including malnutrition risks and bone density concerns. Nutrition and Long-Term Risks Dr. Almandoz warns of malnutrition and lean mass loss among patients using potent weight-loss medications, especially when combined with low-quality diets. He highlights the need for dietary counseling, micronutrient screening, and follow-up—particularly for postmenopausal women and those with chronic illness. Multidisciplinary Care and Mental Health From registered dietitians to primary care providers, a coordinated care team is key. Dr. Almandoz advocates for mental health screening, SMART goal-setting, and destigmatized obesity treatment, recognizing that each patient's health goals and progress vary. Personalized and Precision Medicine in Obesity As newer medications target different biological pathways, Dr. Almandoz calls for a precision approach to obesity care—matching treatment combinations to the individual's physiology, comorbidities, and life context, rather than applying a one-size-fits-all model. Key Takeaway: Obesity is a chronic disease requiring lifelong care. Neither surgery nor medication alone is curative—personalized, multidisciplinary strategies that address nutrition, mental health, and physical health are essential to improving outcomes and quality of life. Resources & Links: Website: MD Newsline Newsletter: Subscribe Here Connect with Dr. Jamie Almandoz: LinkedIn

In this episode of MD Newsline, Dr. Janelle Duah, a specialist in internal medicine, obesity, and lifestyle medicine, discusses the evolving understanding of obesity as a chronic disease rather than a personal failing. She explains the neurobiological, physiological, psychological, and environmental factors that contribute to weight gain, highlighting why traditional methods of diet and exercise alone often fail. Dr. Duah also explores the latest FDA-approved weight loss medications, the impact of gut microbiome on obesity, and how personalized treatment plans can lead to better patient outcomes. Episode Highlights: Understanding Obesity as a Chronic Disease Obesity is no longer seen as simply a result of poor diet and lack of exercise. It is now recognized as a chronic, relapsing disease influenced by genetics, hormones, gut microbiome, and environmental factors. The brain's hypothalamus regulates body weight through a set point that is affected by external inputs such as food quality, stress levels, medications, and even media exposure. This obesogenic environment makes weight management more complex than ever. The Gut Microbiome's Role in Weight Regulation Dr. Duah explains how gut bacteria composition differs between individuals with obesity and those with normal weight, influencing metabolism, inflammation, and energy storage. Research has even explored fecal microbiota transplants as a potential intervention, though diet and lifestyle adjustments remain key in optimizing gut health. She highlights the importance of fiber intake, reducing inflammatory foods, and supporting beneficial gut bacteria for effective weight management. Treatment Options: Medications and Beyond The landscape of obesity treatment has expanded significantly, with FDA-approved medications proving to be effective alternatives to surgery. GLP-1 receptor agonists, such as Ozempic (semaglutide) and Zepbound (tirzepatide), have revolutionized obesity management by helping patients lose 15–40% of their body weight while also benefiting metabolic health. Dr. Duah discusses the benefits and limitations of weight loss medications, including their impact on hormones, cognitive function, and inflammation-related conditions like PCOS and perimenopause. The Future of Obesity Treatment Looking ahead, Dr. Duah envisions a future where obesity is fully recognized as a medical condition, leading to greater insurance coverage for effective treatments. She hopes to see fewer weight-related comorbidities, reduced stigma, and better education for both patients and healthcare providers. She also emphasizes the importance of personalized medicine in tailoring treatments to each individual's genetics, lifestyle, and health goals. Key Takeaway: Obesity is a chronic disease influenced by genetics, hormones, gut health, and environmental factors—not just diet and exercise. New treatments, including GLP-1 medications, offer effective weight management solutions. Greater awareness, personalized care, and improved access to treatments can help reduce obesity-related health risks. Resources & Links: Website: MD Newsline Newsletter: Subscribe Here Connect with Dr. Janelle Duah: Yale School of Medicine